

PD DR. MED. JANA ORTMANN

Fachärztin für Innere Medizin FMH und Angiologie FMH

MEDIZINISCHE AUSBILDUNG

- 10/94 - 09/97 Medizinstudium, Medizinische Fakultät der Friedrich-Schiller Universität, Jena, *Jena, Deutschland*
- 10/97 - 05/01 Medizinstudium, Medizinische Fakultät der Ruprecht Karls Universität Heidelberg, *Heidelberg, Deutschland*
- 09/98 - 10/98 NHS Trust Hospital London, Klinik für Kardiologie und Endokrinologie, *London, Grossbritannien*
- 07/99 - 10/99 Medical School Klinik und Innere Medizin und Public Health, *University of Accra, Ghana*
- 04/00 – 08/00 Louisiana State University, Medical School, Department für Notfallmedizin, *New Orleans, U.S.A.*
- 08/00 - 12/00 University Hospital Tygerberg, Medical School, Klinik für Chirurgie, *Kapstadt, Süd Afrika*
- 10/97 - 06/02 Dissertation, Labor für Molekulare Biologie, Department für Endokrinologische Gynäkologie, Ruprecht-Karls Universität, Medizinische Fakultät, *Heidelberg Deutschland*

AERZTLICHE TÄTIGKEITEN

- 08/01 - 12/01 Facharztausbildung, Universitätsspital „Benjamin Franklin“, Medizinische Fakultät, Freie Universität *Berlin/Deutschland*
- 01/02 - 06/02 Forschungsstipendium, Laboratory for Cardiovascular Genetics „InCor“ Heart Institute, University of *Sao Paulo, Brazil*
- 07/02 - 09/03 Forschungsgruppenleiterin, Labor für Molekularbiologie, Biochemie und Zellkultur, Labor für klinische Atheroskleroseforschung, Klinik für Innere Medizin, Universitätsspital *Zürich*
- 10/03 - 09/05 Facharztausbildung, Klinik für Innere Medizin, Universitätsspital *Zürich*
- 10/05 - 12/05 Facharztausbildung, Klinik für Innere Medizin, Spital *Horgen*
- 01/06 - 12/07 Facharztausbildung, Klinik für Innere Medizin, Kantonsspital *Zug*
- 01/08–12/10 Facharztausbildung, Klinik für Angiologie, Schweizerisches Herz- und Gefässzentrum, Universitätsspital *Bern*
- Seit 01/11 Oberärztin, Department für Klinische Forschung, Universität *Bern*
- 03/12-12/13 Oberärztin für Innere Medizin, Spital Tiefenau, Spitalnetz *Bern*
- 03/14-02/15 Oberärztin für Angiologie und Innere Medizin, Spital *Zofingen*
- 01/14-09/15 Oberärztin für Innere Medizin, Chirurgie Team Bern, Lindenhofspital, *Bern*
- Seit 10/15 Venen- und Gefässpraxis Seeland, *Aarberg*

QUALIFIKATIONEN

- 1992 High-School-Diplom, Colonel-White High-School, *Dayton, Ohio, U.S.A.*
- 1994 Abitur, Albert-Schweitzer-Gymnasium, *Erfurt, Deutschland*
- 05/01 Approbation als Aerztin, (equivalent to M.D. degree), Medizinische Fakultät der Ruprecht-Karls Universität *Heidelberg, Deutschland*
- 06/02 Dissertation mit “*summa cum laude*” (“mit höchster Auszeichnung”) mit dem Titel: “Role of Sex-Steroid-Metabolism in the Mamma Carcinoma Cell Lines MCF-7, MDA-MB 435S und T47-D.” Labor für Molekulare Biologie,

Department für Endokrinologische Gynäkologie, Universitätsfrauenklinik,
Ruprecht-Karls Universität *Heidelberg, Deutschland*
10/2007 Facharztprüfung für Innere Medizin, FMH Innere Medizin
06/2010 Facharztprüfung für Angiologie, FMH Angiologie
10/2013 Habilitation und Ernennung zur Privatdozentin der Medizinischen Fakultät der
Universität Bern

AUSZEICHNUNGEN / PREISE

1991-1992 „Stipendium des Deutschen Bundestages“, Congress-Bundestags-Stipendium
der amerikanischen und deutschen Regierung, Colonel-White High-School,
Dayton, Ohio, U.S.A., High School Diploma
01-06/2001 Forschungsstipendium der „Liebermann-Stiftung“, Zürich, Laboratory for
Cardiovascular Genetics „InCor“ Heart Institute, University of *Sao Paulo,*
Brasilien
06/02 "summa cum laude" (höchste Auszeichnung) der Ruprecht-Karls Universität,
Heidelberg, Deutschland für die Dissertationsarbeit mit dem Titel: "Cloning of
the 5alpha-Reductase and Role of Sex-Steroid-Metabolism in the Mamma
Carcinoma Cell Lines MCF-7, MDA-MB 435S und T47-D."
2004-2006 Aufnahme in das „Mentoring Programm“ der Universität Zürich, Department
für Klinische Forschung, Division Karriereentwicklung
2005 Betreuung der "Besten Medizinischen Dissertationsarbeit 2005" Fakultät der
Universität Zürich, Title: "Acute effects of 17b-estradiol on expression of sex
steroid receptors in blood vessels of patients with coronary atherosclerosis"
von Matthias Meyer
2008 Gewinnerin der Projektförderung 2008, Herzstiftung Olten für das Projekt
"Role for selective activation of estrogen receptor alpha, -beta and G-coupled
protein estrogen receptor for vascular smooth muscle cells under high
glucose conditions"

PROJEKTFÖRDERUNG

06/2008 27000,-CHF gestiftet von der Olten Heart Foundation, Schweiz für das
Projekt "Mechanisms of peripheral artery calcification in patients with diabetes
undergoing infrageneal amputation: characterization of gender differences
using a "bedside to bench" approach"
11/2010 44000,-CHF gestiftet von der Swiss Heart Foundation, Schweiz für das
Projekt "Mechanisms of peripheral artery calcification in patients with diabetes
undergoing infrageneal amputation: characterization of gender differences
using a "bedside to bench" approach"

BETREUTE DISSERTATIONEN

- 1) *Matthias Meyer (2005)*; „Acute effects of 17β-estradiol on expression of sex steroid receptors in blood vessels of patients with coronary atherosclerosis“. Clinic and Policlinic of Internal Medicine, Head: Prof. W. Vetter, Medical Faculty, University of Zurich, Switzerland
- 2) *Luca Emmanuele (2006)*; *Role of ossification-associated proteins in the human vasculature“ Clinic and Policlinic of Internal Medicine, Head: Prof. W. Vetter, Medical Faculty, University of Zurich, Switzerland
- 3) *Dominik Camenzind (2006)*; „Effect of aging on expression of sex steroid receptors in the

male vascular system“ Clinic and Policlinic of Internal Medicine, Head: Prof. W. Vetter, Medical Faculty, University of Zurich, Switzerland

4) *Regina Strässle (2006)*; „Role of age and gender for vascular expression of sex steroid receptors during atherogenesis“ Clinic and Policlinic of Internal Medicine, Head: Prof. W. Vetter, Medical Faculty, University of Zurich, Switzerland

5) *Sybille Horber (2006)*; „Hepatic and pulmonary regulation of cytokines in allograft recipients during chronic rejection“ Clinic and Policlinic of Internal Medicine, Head: Prof. W. Vetter, Medical Faculty, University of Zurich, Switzerland

6) *Jennifer Celeiro (2006)*; *Role of the vascular endothelin system in experimental autoimmune diabetes“ Clinic and Policlinic of Internal Medicine, Head: Prof. W. Vetter, Medical Faculty, University of Zurich, Switzerland

7) *Corvin Glatzer (2006)*; „Vascular genomics of human-like atherosclerosis: Identification of decorin by cDNA microarray“ Clinic and Policlinic of Internal Medicine, Head: Prof. W. Vetter, Medical Faculty, University of Zurich, Switzerland

8) *Tim Dörflinger (2006)*; Regulatory role of apolipoprotein E for hepatic gene expression and lipid content in non-alcoholic steatohepatitis. Clinic and Policlinic of Internal Medicine, Head: Prof. W. Vetter, Medical Faculty, University of Zurich, Switzerland

9) *Martha Veit (2012)*; “Role of estrogen receptor alpha and beta for proliferation and MMPs in human vascular smooth muscle cells” Departement of Interventional and Clinical Angiology, Inselspital, Medical Faculty, University of Berne, Switzerland

10) *Sandra Zingg (2012)*; “Role of estrogen receptor alpha and beta for oxidative stress formation (ROS) and ERK phosphorylation in human vascular smooth muscle cells” Departement of Interventional and Clinical Angiology, Inselspital, Medical Faculty, University of Berne, Switzerland

11) *Gian Cajöri (2012)*; “Novel mechanisms in advanced atherosclerotic arteries of patients undergoing below knee amputation for peripheral artery disease” Departement of Interventional and Clinical Angiology, Inselspital, Medical Faculty, University of Berne, Switzerland

PUBLIKATIONEN

ORIGINALARBEITEN

- OR-1 Rabe T, Kowald A, **Ortmann J**, Rehberger-Schneider S. Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro. *Gynecol Endocrinol* 14(4):223-30, 2000.
- OR-2 **Ortmann J**, Prifti S, Bohlmann MK, Rehberger-Schneider S, Strowitzki T, Rabe T. Testosterone and 5 alpha-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines. *Gynecol Endocrinol* 16(2):113-20, 2002.
- OR-3 Emmanuele L, **Ortmann J** (equal contribution), Doerflinger T, Traupe T, Barton M. Lovastatin stimulates human vascular smooth muscle cell expression of bone morphogenetic protein-2, a potent inhibitor of low-density lipoprotein-stimulated cell growth. *Biochem Biophys Res Commun* 302(1):67-72, 2003.
- OR-4 **Ortmann J**, Traupe T, Nett P, Celeiro J, Hofmann-Lehmann R, Lange M, Vetter W, Barton M. Upregulation of vascular ETB receptor gene expression after chronic ETA receptor blockade in prediabetic NOD mice. *J Cardiovasc Pharmacol* 44:S105-8, 2004.
- OR-5 Traupe T, Lang M, **Ortmann J**, Keller M, Fojtu E, Vetter W, Barton M. Amiodarone acutely inhibits vascular activity of endothelin-converting enzymes. *J Cardiovasc Pharmacol* 44:S113-6, 2004.

- OR-6 **Ortmann J**, Amann K, Brandes RP, Kretzler M, Münter K, Parekh N, Traupe T, Lange M, Lattmann T, Barton M. Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition. *Hypertension* 44(6):974-81, 2004.
- OR-7 Lattmann T, Hein M, Horber S, **Ortmann J**, Teixeira MM, Souza DG, Haas E, Tornillo L, Münter K, Vetter W, Barton M. Activation of pro-inflammatory and anti-inflammatory cytokines in host organs during chronic allograft rejection: Role of endothelin receptor signaling. *Am J Transplant* 5(5):1042-9, 2005.
- OR-8 **Ortmann J**, Nett P, Traupe T, Celeiro J, Tornillo L, Hofmann-Lehmann R, Frank B, Lange M, Vetter W, Barton M. Endothelin inhibition delays onset of hyperglycemia and associated vascular injury in type I diabetes: evidence for endothelin release by pancreatic islet beta-cells. *Biochem Biophys Res Commun* 334(2):689-95, 2005.
- OR-9 Traupe T, **Ortmann J**, Haas E, Munter K, Parekh N, Hofmann-Lehmann R, Baumann K, Barton M. Endothelin ETA receptor blockade with darusentan increases sodium and potassium excretion in aging rats. *J Cardiovasc Pharmacol* 47(3):456-62, 2006.
- OR-10 Nett P, **Ortmann J**, Celeiro J, Hofmann-Lehmann R, Tornillo L, Terraciano LM, Barton M. Transcriptional regulation of vascular bone morphogenetic protein by endothelin receptors in early autoimmune diabetes mellitus. *Life Sci* 78(19):2213-8, 2006.
- OR-11 Lattmann T, **Ortmann J** (equal contribution), Horber S, Shaw SG, Hein M, Barton M. Upregulation of endothelin converting enzyme-1 in host liver during chronic cardiac allograft rejection. *Exp Biol Med* 231(6):899-901, 2006.
- OR-12 **Ortmann J**, Nett PC, Celeiro J, Hofmann-Lehmann R, Tornillo L, Terraciano LM, Barton M. Downregulation of renal endothelin-converting enzyme 2 expression in early autoimmune diabetes. *Exp Biol Med* 231(6):1030-3, 2006.
- OR-13 Di Santo S, Diehm N, **Ortmann J**, Völzmann J, Yang Z, Keo HH, Baumgartner I, Kalka C. Oxidized low density lipoprotein impairs endothelial progenitor cell function by downregulation of E-selectin and integrin alpha(v)beta5. *Biochem Biophys Res Commun* 373(4):528-32, 2008.
- OR-14 Willenberg T, Diehm N, Zwahlen M, Kalka C, Do D, Gretener S, **Ortmann J**, Baumgartner I. Impact of long-term corticosteroid therapy on the distribution pattern of lower limb atherosclerosis. *Eur J Vasc Endovasc Surg*. 2010.
- OR-15 Yang Z, Di Santo S, Diehm N, **Ortmann J**, Völzmann J, Baumgartner I, Kalka C. Paracrine factors secreted by endothelial progenitor cells prevent oxidative stress-induced apoptosis of mature endothelial cells. *Atherosclerosis*. 2010 Jul;211(1):103-9.
- OR-16 **Ortmann J**, Veith M, Zingg S, Di Santo S, Traupe T, Yang Z, Völzmann J, Christen S, Baumgartner I. Selective activation of estrogen receptor alpha inhibits high glucose induced VSMC proliferation by down-regulation of ROS and ERK-phosphorylation. *J Clin Endocrinol Metab*. 2011 Jan;96(1):220-8.
- OR-17 **Ortmann J**, Nüesch E, Cajöri G, Diehm N, Dick F, Traupe T, Baumgartner I. Benefit of immediate revascularization in women with critical limb ischemia in an intention-to-treat analysis. *J Vasc Surg*. 2011 Dec;54(6):1668-78
- OR-18 **Ortmann J**, Nüesch E, Traupe T, Diehm N, Baumgartner I. Gender is an independent risk factor for distribution pattern and lesion morphology in chronic critical limb ischemia. *J Vasc Surg*. 2012 Jan;55(1):98-104
- OR-19 **Ortmann J**, Gahl B, Diehm N, Dick F, Traupe T, Baumgartner I. Survival benefits of revascularization in patients with critical limb ischemia and renal insufficiency. *J Vasc Surg*. 2012 Sep;56(3):737-745
- OR-20 Traupe T, **Ortmann J**, Stoller M, Baumgartner I, de Marchi S, Seiler C. Direct Quantitative Assessment of the Peripheral Artery Collateral Circulation in Patients Undergoing Angiography. *Circulation* 2013 Aug 13;128(7):737-44

FALLBERICHTE

- CR-1 Bohlmann MK, Hornemann A, Weichert J, Stichtenoth G, **Ortmann J**, Diedrich K, Lüdders DW. Off-label use of aromatase inhibitors: An alternative in reproductive medicine and in other nonmammary diseases? *Gynäkologische Endokrinologie*, 2008, Volume 6, Number 4, Seiten 221-228

- CR-2 Bohlmann MK, Hornemann A, **Ortmann J**, Thill M, Diedrich K, Luedders DW Anticoagulation and assisted reproduction: Improved pregnancy and birth rates through additional therapy with aspirin and heparin? *Gynäkologische Endokrinologie*, 2009, Volume 7, Number 2, Seiten 74-79
- CR-3 **Ortmann J**, Widmer MK, Gretener S, Do DD, Willenberg T, Daliri A, Baumgartner I. Cystic adventitial degeneration: ectopic ganglia from adjacent joint capsules. *Vasa*. 2009 Nov;38(4):374-7.

BUCHKAPITEL

- BC-1 Zouboulis CC, Fimmel S, **Ortmann J**, Turnbull JR, Boschnakow A. Sebaceous Glands. In: Hoath SB, Maibach H (eds.) *Neonatal Skin – Structure and Function*. 2nd ed. *Deckker M, New York Basel Citations: 13*

REVIEW ARTIKEL

- R-1 Barton M, Carmona R, **Ortmann J**, Krieger JE, Traupe T. Obesity-associated activation of angiotensin and endothelin in the cardiovascular system. *Int J Biochem Cell Biol*. 2003;35(6):826-37
- R-2 Traupe T, **Ortmann J**, Münter K, Barton M. Endothelial therapy of atherosclerosis and its risk factors. *Curr Vasc Pharmacol* 2003;111-21
- R-3 **Ortmann J**, Traupe T, Vetter W, Barton M. Postmenopausal hormone replacement therapy and cardiovascular risk: role of conjugated equine estrogens and medroxyprogesterone acetate. *Schweiz Rundsch Med Prax* 2004;904-14

VARIA

- DT-1 Doctorate thesis entitled "Role of Sex-Steroid-Metabolism in the Mamma Carcinoma Cell Lines MCF-7, MDA-MB 435S und T47-D." Laboratory for Molecular Biology, Department of Endocrinological Gynecology, Head: Prof. T. Rabe, Womens Hospital Ruprecht-Karls University, *Heidelberg, Germany*